HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.

Abstract
Nanoimmunotherapy, the application of nanotechnology for sustained and targeted delivery of antigens to dendritic cells (DCs), has attracted much attention in stimulating antigen-specific immune response for antitumor therapy. In order to in situ deliver antigens to DCs for efficient antigen presentation and subsequent induction of strong cytotoxic T lymphocytes (CTL) response, here we developed a multi-peptide (TRP2180-188 and HGP10025-33) and toll-like receptor 4 agonist (monophosphoryl lipid A) codelivery system based on lipid-coated zinc phosphate hybrid nanoparticles (LZnP NPs). This delivery system equips with the chelating property of zinc to realize the high encapsulation efficiency with antigenic peptides and the influence on immune system with adjuvant-like feature. The combination of H-2K(b) and H-2D(b)-restricted peptides could provide multiple epitopes as the target of specific MHC alleles, making tumor more difficult to escape from the surveillance of immune system. The formulated LZnP nano-vaccine with the size of 30nm and outer leaflet lipid exhibited antitumor immunity as the secretion of cytokines in vitro and increased CD8(+) T cell response from IFN-γ ELISPOT analysis ex vivo. The antitumor effects were further evidenced from the prophylactic, therapeutic and metastatic melanoma tumor models compared with free antigens and single peptide-loaded nano-vaccines. These results validate the benefit of LZnP-based vaccine for antitumor immunity and indicate that co-delivery of tumor antigens along with adjuvant may be an optimized strategy for tumor immunotherapy.
AuthorsXiangting Zhuang, Tingting Wu, Yongdan Zhao, Xiaomeng Hu, Yuling Bao, Yuanyuan Guo, Qingle Song, Gao Li, Songwei Tan, Zhiping Zhang
JournalJournal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 228 Pg. 26-37 (Apr 28 2016) ISSN: 1873-4995 [Electronic] Netherlands
PMID26921522 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016. Published by Elsevier B.V.
Chemical References
  • Adjuvants, Immunologic
  • Antigens, Neoplasm
  • Cancer Vaccines
  • Cytokines
  • Drug Carriers
  • Lipid A
  • Peptides
  • Phosphates
  • Toll-Like Receptor 4
  • Zinc Compounds
  • zinc phosphate
  • monophosphoryl lipid A
Topics
  • Adjuvants, Immunologic (administration & dosage, therapeutic use)
  • Animals
  • Antigens, Neoplasm (administration & dosage, therapeutic use)
  • CD8-Positive T-Lymphocytes (immunology, pathology)
  • Cancer Vaccines (administration & dosage, therapeutic use)
  • Cytokines (immunology)
  • Dendritic Cells (immunology, pathology)
  • Drug Carriers (chemistry)
  • Female
  • Humans
  • Immunotherapy
  • Lipid A (administration & dosage, analogs & derivatives, therapeutic use)
  • Melanoma (immunology, pathology, therapy)
  • Mice, Inbred C57BL
  • Nanoparticles (chemistry)
  • Peptides (administration & dosage, therapeutic use)
  • Phosphates (chemistry)
  • Toll-Like Receptor 4 (agonists)
  • Zinc Compounds (chemistry)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: